Sort   by:  
 Page size 
UnknownPrimary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC.
Not available
S-EPMC12005273 | biostudies-literature
UnknownA noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens.
Not available
S-EPMC7754298 | biostudies-literature
UnknownClinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial.
Not available
S-EPMC8862451 | biostudies-literature
UnknownAchievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC.
Not available
S-EPMC5233871 | biostudies-literature
UnknownTreating EGFR mutation resistance in non-small cell lung cancer - role of osimertinib.
Not available
S-EPMC5536882 | biostudies-literature
UnknownProfile of bavituximab and its potential in the treatment of non-small-cell lung cancer.
Not available
S-EPMC5217514 | biostudies-literature
UnknownTargeting MET in NSCLC: looking for a needle in a haystack.
Not available
S-EPMC4367673 | biostudies-literature
UnknownHow selecting best upfront therapy for metastatic disease?-Focus on ROS1-rearranged disease.
Not available
S-EPMC7815342 | biostudies-literature
UnknownKRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges.
Not available
S-EPMC9408881 | biostudies-literature
UnknownNon-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations.
Not available
S-EPMC12775477 | biostudies-literature
Sort   by:  
 Page size